Last checked at 11 Apr 2012 07:00
For immediate release | 11 April 2012 |
ANGLE plc
("ANGLE" or "the Company")
NOVOCELLUS EMBRYOSURE® TRIAL STARTED
ANGLE plc (AIM: AGL), the technology commercialisation company, is pleased to announce that the clinical trial for Novocellus' product EmbryoSure®, for IVF embryo viability, has now commenced.
Novocellus, which is 92% owned by ANGLE, has a partnership with ORIGIO, a leading supplier of specialised IVF products. ORIGIO has the right to license the EmbryoSure® IP in exchange for milestone payments and a royalty on future net sales.
Approval has been received from the MHRA (Medicines and Healthcare products Regulatory Agency) for the amended EmbryoSure® trial and patient recruitment is being initiated this week.
Four leading UK IVF clinics are participating in the trial namely:
·; Hammersmith: IVF Hammersmith Ltd at Hammersmith Hospital, which has a five star rating (the highest possible) in the university research assessment exercise;
·; CARE Manchester: CARE Fertility, the UK's largest independent provider of assisted conception cycles, around 2,000 annually;
·; Leeds: The Leeds Centre for Reproductive Medicine (LCRM), one of the largest and most comprehensive services within the UK. Over 1,500 new patients are seen on an annual basis;
·; Liverpool: Liverpool Women's NHS Foundation Trust dedicated to the healthcare of women, babies and their families. The Hewitt Centre for Reproductive Medicine is the largest centre of its kind in Europe and one of the biggest providers of NHS fertility treatment in Britain with 1,500 treatment cycles every year.
It is intended to recruit around 400 patients and the trial timescales are progressing according to plan with a target completion in mid-year 2013. Product launch in the UK market is anticipated in mid-year 2014.
ANGLE Founder and Chief Executive, Andrew Newland, commented:
"We are delighted that the EmbryoSure® trial has now started and that the revitalised agreement with ORIGIO is proceeding to plan. EmbryoSure® has the potential to significantly improve the selection of embryos for IVF with the objective of enabling single embryo transfer with increased pregnancy success rates."
For further information:
ANGLE plc Andrew Newland, Chief Executive Ian Griffiths, Finance Director
| 01483 685830 |
Cenkos Securities Stephen Keys, Adrian Hargrave (Nominated adviser) Andy Roberts (Sales)
| 020 7397 8900 |
Buchanan Mark Court, Sophie Cowles
| 020 7466 5000 |
Scott Harris Stephen Scott, Harry Dee | 0207 653 0030 |